Theratechnologies Inc. (THTX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer
Theratechnologies is likely to accept Future Pak's $255 million offer, presenting a 39%-78% premium over current share prices, despite non-binding risks. The company's HIV franchise, led by EGRIFTA SV, faces competition and supply issues, with uncertain prospects for its new formulation and other niche products. Theratechnologies' financials are dire, with only $4.6 million in cash and a high burn rate, necessitating urgent external financing or a strategic transaction.
Theratechnologies Inc. (THTX) Q1 2025 Earnings Call Transcript
Theratechnologies Inc. (NASDAQ:THTX ) Q1 2025 Earnings Conference Call April 9, 2025 8:30 AM ET Company Participants Joanne Choi - Senior Director, Investor Relations Paul Levesque - President and Chief Executive Officer Philippe Dubuc - Senior Vice President and Chief Financial Officer John Leasure - Global Commercial Officer Conference Call Participants Andre Uddin - Research Capital Justin Walsh - Jones Trading Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies First Quarter 2025 Earnings Call.
Theratechnologies Inc. (THTX) Q4 2024 Earnings Call Transcript
Theratechnologies Inc. (NASDAQ:THTX ) Q4 2024 Earnings Conference Call February 26, 2024 8:30 AM ET Company Participants Joanne Choi - Senior Director, Investor Relations Paul Levesque - President & CEO Philippe Dubuc - SVP & CFO John Leasure - Global Commercial Officer Conference Call Participants Andre Uddin - Research Capital Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies Fourth Quarter and Fiscal Year 2024 Earnings Call.
Theratechnologies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 67,662.75 | $820,072.53 | $229,376.72 | -$590,695.81 | -72.03% |
Theratechnologies Inc. (THTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Theratechnologies Inc. ever had a stock split?
Theratechnologies Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Paul Lévesque CEO | NASDAQ (CM) Exchange | 88338H704 CUSIP |
| CA Country | 103 Employees | - Last Dividend | 31 Jul 2023 Last Split | - IPO Date |
Overview
Theratechnologies Inc. is a biopharmaceutical company with a strong focus on addressing unmet medical needs through the development and commercialization of innovative therapies. Established in 1993, the company operates in the United States, Canada, and Europe, targeting conditions associated with HIV, such as lipodystrophy, and engaging in the development of treatments for cancers like triple negative breast cancer and ovarian cancer. This reflects Theratechnologies' commitment to improving the quality of life of patients living with chronic diseases and conditions.
Products and Services
EGRIFTA and EGRIFTA SV: These are Theratechnologies' products aimed at reducing excess abdominal fat in HIV-infected patients suffering from lipodystrophy. The condition known as lipodystrophy is often characterized by abnormal fat distribution and can significantly affect the quality of life of those living with HIV. By targeting this specific complication, EGRIFTA and EGRIFTA SV provide a focused therapeutic solution contributing to the well-being and health of the affected patient population.
Trogarzo (ibalizumab injection): This product represents a significant advancement in the treatment of HIV-1 infection, especially for patients with multidrug-resistant forms of the virus. Trogarzo, administered as an injection, works by targeting a different aspect of the HIV virus lifecycle compared to traditional antiretroviral therapies, offering a new hope for patients who have limited treatment options due to resistance issues.
F8 Formulation: Currently in development, the F8 Formulation aims to treat lipodystrophy in people living with HIV. As the company's research advances, this product has the potential to further address the needs of HIV patients grappling with lipodystrophy, improving upon existing treatments and expanding the range of options available.
TH1902: This is a drug in early-phase clinical trials for the treatment of triple negative breast cancer. Triple negative breast cancer is a particularly aggressive and hard-to-treat form of the disease, lacking the three receptors known to fuel most breast cancer growth—estrogen, progesterone, and the HER-2/neu gene. TH1902 represents Theratechnologies' venture into oncology, with the aim of bringing new solutions to this challenging area of cancer treatment.
TH1904: Another investigational drug focusing on the treatment of ovarian cancer. Ovarian cancer is known for being difficult to diagnose early and requires more effective treatment options. TH1904's development underscores Theratechnologies' commitment to addressing hard-to-treat cancers and enhancing the arsenal against ovarian cancer.
